Katharina Nöbauer

Katharina Nöbauer

Auto-generated profile, based on publicly available information

Katharina Nöbauer

VetCore Facility for Research, University of Veterinary Medicine, Veterinärplatz 1, 1210, Vienna, Austria

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Donatella TeseiDonatella Tesei
Donatella Tesei
Felice QuartinelloFelice Quartinello
Felice Quartinello
GGGeorg Guebitz
Georg Guebitz
DRDoris Ribitsch
Doris Ribitsch
KNKatharina Nöbauer
Katharina Nöbauer
KSKatja Sterflinger
Katja Sterflinger
Knufia chersonesos is an ascomycotal representative of black fungi, a morphological group of polyextremotolerant melanotic fungi, whose ability to resort to recalcitrant carbon sources makes it an interesting candidate for degradation purposes. A secretome screening towards polyesterases was carried out for the fungus and its non-melanized mutant, grown in presence of the synthetic copolyester Polybutylene adipate terephthalate (PBAT) as additional or sole carbon source, and resulted in the identification of 37 esterolytic and lipolytic enzymes across the established cultivation conditions. Quantitative proteomics allowed to unveil 9 proteins being constitutively expressed at all conditions and 7 which were instead detected as up-regulated by PBAT exposure. Protein functional analysis and structure prediction indicated similarity of these enzymes to microbial polyesterases of known biotechnological use such as MHETase from Ideonella sakaiensis and CalA from Candida antarctica. For both strains, PBAT hydrolysis was recorded at all cultivation conditions and primarily the corresponding monomers were released, which suggests degradation to the polymer’s smallest building block. The work presented here aims to demonstrate how investigations of the secretome can provide new insights into the eco-physiology of polymer degrading fungi and ultimately aid the identification of novel enzymes with potential application in polymer processing, recycling and degradation.

8 June 2022 in Archives of Toxicology
Verified
Journal Article
Open access
PDF file
LSLaura Soler
Laura Soler
Ingrid MillerIngrid Miller
Ingrid Miller
CTChloé Terciolo
Chloé Terciolo
KHKarin Anna Hummel
Karin Anna Hummel
KNKatharina Nöbauer
Katharina Nöbauer
Isabelle OswaldIsabelle Oswald
Isabelle Oswald
NX is a type A trichothecene produced by Fusarium graminearum with limited information on its toxicity. NX is structurally similar to deoxynivalenol (DON), only differing by the lacking keto group at C8. Because of the structural similarity of the two toxins as well as their potential co-occurrence in food and feed, it is of interest to determine the toxicity of this new compound. In this study, we compared the protein composition of the extracellular media of pig intestinal explants (secretome) exposed to 10 µM of DON or NX for 4 h compared with controls. The combination of two complementary quantitative proteomic approaches (a gel-based and a gel-free approach) identified 18 and 23 differentially abundant proteins (DAPs) for DON and NX, respectively, compared to controls. Functional analysis suggested that, whereas DON toxicity was associated with decreased cell viability and cell destruction, NX toxicity was associated with an enrichment of mitochondrial proteins in the secretome. The presence of these proteins may be associated with the already known ability of NX to induce an intestinal inflammation. Overall, our results indicated that DON- and NX-induced changes in the extracellular proteome of intestinal explants are different. The increased leakage/secretion of mitochondrial proteins by NX may be a feature of NX toxicity.

1 August 2012 in Thrombosis Research
Verified
Journal Article
Closed access
JSJolanta M. Siller-Matula
Jolanta M. Siller-Matula
Ingrid MillerIngrid Miller
Ingrid Miller
MGManfred Gemeiner
Manfred Gemeiner
Roberto PlasenzottiRoberto Plasenzotti
Roberto Plasenzotti
GBGuenther Bayer
Guenther Bayer
BJBernd Jilma
Bernd Jilma

20 December 2019 in Planta Medica
Verified
Conference Paper
Closed access
SAS Axmann
S Axmann
KHK Hummel
K Hummel
KNK Nöbauer
K Nöbauer
ERE Razzazi-Fazeli
E Razzazi-Fazeli
KZKarin Zitterl-Eglseer
Karin Zitterl-Eglseer
Devil’s claw is used for the treatment of chronic inflammatory symptoms and degenerative disorders [1] in horses since many years, but without the substantive equine pharmacokinetic data [2],[3],[4]. The pharmacokinetic parameters of harpagoside, the main active constituent of Harpagophytum procumbens DC ex Meisn., were evaluated in equine plasma after administration of Harpagophytum extract FB 8858 in an open, single-dose, two-treatment, two-period, randomised cross-over design. Six horses received a single dose of Harpagophytum extract, corresponding to 5 mg/kg BM harpagoside, and after 7 days washout period, 10 mg/kg BM harpagoside via nasogastric tube. Plasma samples at certain time points (before and 0-24 h after administration) were collected, cleaned up by solid-phase extraction and harpagoside concentrations were determined by LC-MS/MS using apigenin-7-glucoside as internal standard. Plasma concentration-time data and relevant parameters were described by non-compartmental model through PKSolver software. Harpagoside could be detected up to 9 h after administration. Cmax was found at 25.59 and 55.46 ng/ml, t1/2 at 2.53 h and 2.32 h, respectively and tmax at one hour in both trials. AUC0-inf was 70.46 and 117.85 ng h ml-1, respectively. A proportional relationship between dose, Cmax and AUC was observed. Distribution (Vz/F) was 259.04 and 283.83 L/kg and clearance (CL/F) 70.96 and 84.86 L h-1 kg-1, respectively. Treatment of horses with Harpagophytum extract did not cause any clinically detectable side effects. The knowledge of basic equine pharmacokinetics, based on the results of this study, will help to link results from in vitro assays and clinical studies and optimise therapeutic efficacy.

2 October 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Donatella TeseiDonatella Tesei
Donatella Tesei
Felice QuartinelloFelice Quartinello
Felice Quartinello
GGGeorg Guebitz
Georg Guebitz
DRDoris Ribitsch
Doris Ribitsch
KNKatharina Nöbauer
Katharina Nöbauer
KSKatja Sterflinger
Katja Sterflinger
An amendment to this paper has been published and can be accessed via a link at the top of the paper.